Primary Sclerosing Cholangitis-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Primary Sclerosing Cholangitis-Pipeline Review H2 2017” this report provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.
(EMAILWIRE.COM, July 26, 2017 ) Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain chills diarrhea fatigue itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase II Phase I Preclinical and Discovery stages are 8 2 6 and 1 respectively.
Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at Primary Sclerosing Cholangitis-Pipeline Review H2 2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal) .
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881460/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Acorda Therapeutics Inc
Albireo Pharma Inc
Allergan Plc
Conatus Pharmaceuticals Inc
Dr. Falk Pharma GmbH
Gilead Sciences Inc
iCo Therapeutics Inc.
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Sancilio & Company Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Shire Plc
Sirnaomics Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881460/discount
List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Number of Products by Stage and Target H2 2017
Number of Products by Stage and Mechanism of Action H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Primary Sclerosing Cholangitis-Pipeline by Acorda Therapeutics Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Albireo Pharma Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Allergan Plc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Conatus Pharmaceuticals Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Dr. Falk Pharma GmbH H2 2017
Primary Sclerosing Cholangitis-Pipeline by Gilead Sciences Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by iCo Therapeutics Inc. H2 2017
Primary Sclerosing Cholangitis-Pipeline by Intercept Pharmaceuticals Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by NGM Biopharmaceuticals Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Sancilio & Company Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Seres Therapeutics Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Shenzhen HighTide Biopharmaceutical Ltd H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881460/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase II Phase I Preclinical and Discovery stages are 8 2 6 and 1 respectively.
Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at Primary Sclerosing Cholangitis-Pipeline Review H2 2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal) .
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881460/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Acorda Therapeutics Inc
Albireo Pharma Inc
Allergan Plc
Conatus Pharmaceuticals Inc
Dr. Falk Pharma GmbH
Gilead Sciences Inc
iCo Therapeutics Inc.
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Sancilio & Company Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Shire Plc
Sirnaomics Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881460/discount
List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Number of Products by Stage and Target H2 2017
Number of Products by Stage and Mechanism of Action H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Primary Sclerosing Cholangitis-Pipeline by Acorda Therapeutics Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Albireo Pharma Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Allergan Plc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Conatus Pharmaceuticals Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Dr. Falk Pharma GmbH H2 2017
Primary Sclerosing Cholangitis-Pipeline by Gilead Sciences Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by iCo Therapeutics Inc. H2 2017
Primary Sclerosing Cholangitis-Pipeline by Intercept Pharmaceuticals Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by NGM Biopharmaceuticals Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Sancilio & Company Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Seres Therapeutics Inc H2 2017
Primary Sclerosing Cholangitis-Pipeline by Shenzhen HighTide Biopharmaceutical Ltd H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881460/buy/2000
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results